The Institute for Clinical and Economic Review (ICER) announced Thursday, April 11, that it will review the comparative clinical effectiveness and value of several treatments for type 2 diabetes.
According to a press release, ICER will assess Novo Nordisk’s oral semaglutide and compare it to Novo Nordisk’s liraglutide, Boehringer Ingelheim and Eli Lilly’s empaglifozin and Merck’s sitagliptin.
The Food and Drug Administration is expected to make a decision on oral semaglutide in the second half of this year.
ICER’s report will be reviewed at the November meeting of the New England Comparative Effectiveness Public Advisory Council.
To read the full press release on ICER’s website, click here.